Stay updated on Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:12:55.000Z thumbnail image
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the antitumor activity investigation of tipifarnib in subjects with advanced tumors carrying HRAS mutations and no standard curative therapy available, specifically focusing on Squamous Cell Carcinoma Head and Neck Cancer and other Squamous Cell Carcinoma types.
    Difference
    0.1%
    Check dated 2024-06-06T14:18:50.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Summary
    The webpage has updated the 'Participation Criteria' section to include detailed eligibility criteria for participants, specifying the types of thyroid cancer and Squamous Cell Carcinoma, as well as other health conditions and prior treatments required for inclusion in the study. Previously, no information was provided in this section.
    Difference
    21%
    Check dated 2024-05-22T21:00:26.000Z thumbnail image
  8. Check
    45 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:02:30.000Z thumbnail image

Stay in the know with updates to Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page.